chevron_leftBack
As of 24 April 2025, Bonesupport Holding AB (publ) has a market cap of $2.18B USD, ranking #5088 globally and #79 in Sweden. It ranks #461 in the Healthcare sector, and #45 in the Medical Instruments & Supplies industry.
Key Stats
Market Cap
$2.18BUSD
20.9B SEK
Enterprise Value
$2.14BUSD
20.69B SEK
Revenue (TTM)
$93.63MUSD
898.73M SEK
EBITDA (TTM)
$15.48MUSD
149.9M SEK
Net Income (TTM)
$13.93MUSD
133.75M SEK
EBITDA Margin
17%
Profit Margin
15%
PE Ratio
157.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Emil Billbäck
open_in_new
Employees
118
Founded
1999
Website
bonesupport.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 1.1% | 3.9% | -3.1% | -9.4% | -4.9% | 32% |
Upcoming Earnings
Earnings Date
Thu, Apr 24
Today
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
BONEX
Bonesupport Holding AB
ISIN: SE0009858152
Shares Out.:
Shares Outstanding:
65.859M1
Shares Float:
55.141M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
321.00 SEK | |
|
0RQO
Bonesupport Holding AB
ISIN: SE0009858152
|
321.60 SEK | |
|
BOEUF
ISIN: SE0009858152
Shares Out.:
Shares Outstanding:
65.859M1
Shares Float:
55.141M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
28.40 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Bonesupport Holding AB (publ)
Bonesupport Holding AB (publ), an orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management. In addition, the company develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. The company was founded in 1999 and is headquartered in Lund, Sweden.
